Report on EU-USA Workshop: How Systems Biology Can Advance Cancer Research (27 October 2008)

Ruedi Aebersold, Charles Auffray, Erin Baney, Emmanuel Barillot, Alvis Brazma, Catherine Brett, Søren Brunak, Atul Butte, Andrea Califano, Julio Celis, Tanja Čufer, James Ferrell, David Galas, Daniel Gallahan, Robert Gatenby, Albert Goldbeter, Nataša Hace, Adriano Henney, Lee Hood, Ravi IyengarVicky Jackson, Ollie Kallioniemi, Ursula Klingmüller, Patrik Kolar, Walter Kolch, Christina Kyriakopoulou, Frank Laplace, Hans Lehrach, Frederick Marcus, Lynn Matrisian, Garry Nolan, Lucas Pelkmans, Anil Potti, Chris Sander, Marija Seljak, Dinah Singer, Peter Sorger, Hendrik Stunnenberg, Giulio Superti-Furga, Mathias Uhlen, Marc Vidal, John Weinstein, Dennis A Wigle, Michael Williams, Olaf Wolkenhauer, Boris Zhivotovsky, Andrei Zinovyev, Blaž Zupan

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The main conclusion is that systems biology approaches can indeed advance cancer research, having already proved successful in a very wide variety of cancer-related areas, and are likely to prove superior to many current research strategies. Major points include:•Systems biology and computational approaches can make important contributions to research and development in key clinical aspects of cancer and of cancer treatment, and should be developed for understanding and application to diagnosis, biomarkers, cancer progression, drug development and treatment strategies.•Development of new measurement technologies is central to successful systems approaches, and should be strongly encouraged. The systems view of disease combined with these new technologies and novel computational tools will over the next 5-20 years lead to medicine that is predictive, personalized, preventive and participatory (P4 medicine).•Major initiatives are in progress to gather extremely wide ranges of data for both somatic and germ-line genetic variations, as well as gene, transcript, protein and metabolite expression profiles that are cancer-relevant. Electronic databases and repositories play a central role to store and analyze these data. These resources need to be developed and sustained.•Understanding cellular pathways is crucial in cancer research, and these pathways need to be considered in the context of the progression of cancer at various stages. At all stages of cancer progression, major areas require modelling via systems and developmental biology methods including immune system reactions, angiogenesis and tumour progression.•A number of mathematical models of an analytical or computational nature have been developed that can give detailed insights into the dynamics of cancer-relevant systems. These models should be further integrated across multiple levels of biological organization in conjunction with analysis of laboratory and clinical data.•Biomarkers represent major tools in determining the presence of cancer, its progression and the responses to treatments. There is a need for sets of high-quality annotated clinical samples, enabling comparisons across different diseases and the quantitative simulation of major pathways leading to biomarker development and analysis of drug effects.•Education is recognized as a key component in the success of any systems biology programme, especially for applications to cancer research. It is recognized that a balance needs to be found between the need to be interdisciplinary and the necessity of having extensive specialist knowledge in particular areas.•A proposal from this workshop is to explore one or more types of cancer over the full scale of their progression, for example glioblastoma or colon cancer. Such an exemplar project would require all the experimental and computational tools available for the generation and analysis of quantitative data over the entire hierarchy of biological information. These tools and approaches could be mobilized to understand, detect and treat cancerous processes and establish methods applicable across a wide range of cancers.

Original languageEnglish (US)
Pages (from-to)9-17
Number of pages9
JournalMolecular Oncology
Volume3
Issue number1
DOIs
StatePublished - Feb 2009

Fingerprint

Systems Biology
Education
Research
Neoplasms
Biomarkers
Medicine
Technology
Developmental Biology
Glioblastoma
Tumor Biomarkers
Germ Cells
Pharmaceutical Preparations
Colonic Neoplasms
Immune System

Keywords

  • Cancer
  • EU-USA workshop
  • Systems biology

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Aebersold, R., Auffray, C., Baney, E., Barillot, E., Brazma, A., Brett, C., ... Zupan, B. (2009). Report on EU-USA Workshop: How Systems Biology Can Advance Cancer Research (27 October 2008). Molecular Oncology, 3(1), 9-17. https://doi.org/10.1016/j.molonc.2008.11.003

Report on EU-USA Workshop : How Systems Biology Can Advance Cancer Research (27 October 2008). / Aebersold, Ruedi; Auffray, Charles; Baney, Erin; Barillot, Emmanuel; Brazma, Alvis; Brett, Catherine; Brunak, Søren; Butte, Atul; Califano, Andrea; Celis, Julio; Čufer, Tanja; Ferrell, James; Galas, David; Gallahan, Daniel; Gatenby, Robert; Goldbeter, Albert; Hace, Nataša; Henney, Adriano; Hood, Lee; Iyengar, Ravi; Jackson, Vicky; Kallioniemi, Ollie; Klingmüller, Ursula; Kolar, Patrik; Kolch, Walter; Kyriakopoulou, Christina; Laplace, Frank; Lehrach, Hans; Marcus, Frederick; Matrisian, Lynn; Nolan, Garry; Pelkmans, Lucas; Potti, Anil; Sander, Chris; Seljak, Marija; Singer, Dinah; Sorger, Peter; Stunnenberg, Hendrik; Superti-Furga, Giulio; Uhlen, Mathias; Vidal, Marc; Weinstein, John; Wigle, Dennis A; Williams, Michael; Wolkenhauer, Olaf; Zhivotovsky, Boris; Zinovyev, Andrei; Zupan, Blaž.

In: Molecular Oncology, Vol. 3, No. 1, 02.2009, p. 9-17.

Research output: Contribution to journalArticle

Aebersold, R, Auffray, C, Baney, E, Barillot, E, Brazma, A, Brett, C, Brunak, S, Butte, A, Califano, A, Celis, J, Čufer, T, Ferrell, J, Galas, D, Gallahan, D, Gatenby, R, Goldbeter, A, Hace, N, Henney, A, Hood, L, Iyengar, R, Jackson, V, Kallioniemi, O, Klingmüller, U, Kolar, P, Kolch, W, Kyriakopoulou, C, Laplace, F, Lehrach, H, Marcus, F, Matrisian, L, Nolan, G, Pelkmans, L, Potti, A, Sander, C, Seljak, M, Singer, D, Sorger, P, Stunnenberg, H, Superti-Furga, G, Uhlen, M, Vidal, M, Weinstein, J, Wigle, DA, Williams, M, Wolkenhauer, O, Zhivotovsky, B, Zinovyev, A & Zupan, B 2009, 'Report on EU-USA Workshop: How Systems Biology Can Advance Cancer Research (27 October 2008)', Molecular Oncology, vol. 3, no. 1, pp. 9-17. https://doi.org/10.1016/j.molonc.2008.11.003
Aebersold, Ruedi ; Auffray, Charles ; Baney, Erin ; Barillot, Emmanuel ; Brazma, Alvis ; Brett, Catherine ; Brunak, Søren ; Butte, Atul ; Califano, Andrea ; Celis, Julio ; Čufer, Tanja ; Ferrell, James ; Galas, David ; Gallahan, Daniel ; Gatenby, Robert ; Goldbeter, Albert ; Hace, Nataša ; Henney, Adriano ; Hood, Lee ; Iyengar, Ravi ; Jackson, Vicky ; Kallioniemi, Ollie ; Klingmüller, Ursula ; Kolar, Patrik ; Kolch, Walter ; Kyriakopoulou, Christina ; Laplace, Frank ; Lehrach, Hans ; Marcus, Frederick ; Matrisian, Lynn ; Nolan, Garry ; Pelkmans, Lucas ; Potti, Anil ; Sander, Chris ; Seljak, Marija ; Singer, Dinah ; Sorger, Peter ; Stunnenberg, Hendrik ; Superti-Furga, Giulio ; Uhlen, Mathias ; Vidal, Marc ; Weinstein, John ; Wigle, Dennis A ; Williams, Michael ; Wolkenhauer, Olaf ; Zhivotovsky, Boris ; Zinovyev, Andrei ; Zupan, Blaž. / Report on EU-USA Workshop : How Systems Biology Can Advance Cancer Research (27 October 2008). In: Molecular Oncology. 2009 ; Vol. 3, No. 1. pp. 9-17.
@article{8566dcd55b14401caa17514ced51eb74,
title = "Report on EU-USA Workshop: How Systems Biology Can Advance Cancer Research (27 October 2008)",
abstract = "The main conclusion is that systems biology approaches can indeed advance cancer research, having already proved successful in a very wide variety of cancer-related areas, and are likely to prove superior to many current research strategies. Major points include:•Systems biology and computational approaches can make important contributions to research and development in key clinical aspects of cancer and of cancer treatment, and should be developed for understanding and application to diagnosis, biomarkers, cancer progression, drug development and treatment strategies.•Development of new measurement technologies is central to successful systems approaches, and should be strongly encouraged. The systems view of disease combined with these new technologies and novel computational tools will over the next 5-20 years lead to medicine that is predictive, personalized, preventive and participatory (P4 medicine).•Major initiatives are in progress to gather extremely wide ranges of data for both somatic and germ-line genetic variations, as well as gene, transcript, protein and metabolite expression profiles that are cancer-relevant. Electronic databases and repositories play a central role to store and analyze these data. These resources need to be developed and sustained.•Understanding cellular pathways is crucial in cancer research, and these pathways need to be considered in the context of the progression of cancer at various stages. At all stages of cancer progression, major areas require modelling via systems and developmental biology methods including immune system reactions, angiogenesis and tumour progression.•A number of mathematical models of an analytical or computational nature have been developed that can give detailed insights into the dynamics of cancer-relevant systems. These models should be further integrated across multiple levels of biological organization in conjunction with analysis of laboratory and clinical data.•Biomarkers represent major tools in determining the presence of cancer, its progression and the responses to treatments. There is a need for sets of high-quality annotated clinical samples, enabling comparisons across different diseases and the quantitative simulation of major pathways leading to biomarker development and analysis of drug effects.•Education is recognized as a key component in the success of any systems biology programme, especially for applications to cancer research. It is recognized that a balance needs to be found between the need to be interdisciplinary and the necessity of having extensive specialist knowledge in particular areas.•A proposal from this workshop is to explore one or more types of cancer over the full scale of their progression, for example glioblastoma or colon cancer. Such an exemplar project would require all the experimental and computational tools available for the generation and analysis of quantitative data over the entire hierarchy of biological information. These tools and approaches could be mobilized to understand, detect and treat cancerous processes and establish methods applicable across a wide range of cancers.",
keywords = "Cancer, EU-USA workshop, Systems biology",
author = "Ruedi Aebersold and Charles Auffray and Erin Baney and Emmanuel Barillot and Alvis Brazma and Catherine Brett and S{\o}ren Brunak and Atul Butte and Andrea Califano and Julio Celis and Tanja Čufer and James Ferrell and David Galas and Daniel Gallahan and Robert Gatenby and Albert Goldbeter and Nataša Hace and Adriano Henney and Lee Hood and Ravi Iyengar and Vicky Jackson and Ollie Kallioniemi and Ursula Klingm{\"u}ller and Patrik Kolar and Walter Kolch and Christina Kyriakopoulou and Frank Laplace and Hans Lehrach and Frederick Marcus and Lynn Matrisian and Garry Nolan and Lucas Pelkmans and Anil Potti and Chris Sander and Marija Seljak and Dinah Singer and Peter Sorger and Hendrik Stunnenberg and Giulio Superti-Furga and Mathias Uhlen and Marc Vidal and John Weinstein and Wigle, {Dennis A} and Michael Williams and Olaf Wolkenhauer and Boris Zhivotovsky and Andrei Zinovyev and Blaž Zupan",
year = "2009",
month = "2",
doi = "10.1016/j.molonc.2008.11.003",
language = "English (US)",
volume = "3",
pages = "9--17",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Report on EU-USA Workshop

T2 - How Systems Biology Can Advance Cancer Research (27 October 2008)

AU - Aebersold, Ruedi

AU - Auffray, Charles

AU - Baney, Erin

AU - Barillot, Emmanuel

AU - Brazma, Alvis

AU - Brett, Catherine

AU - Brunak, Søren

AU - Butte, Atul

AU - Califano, Andrea

AU - Celis, Julio

AU - Čufer, Tanja

AU - Ferrell, James

AU - Galas, David

AU - Gallahan, Daniel

AU - Gatenby, Robert

AU - Goldbeter, Albert

AU - Hace, Nataša

AU - Henney, Adriano

AU - Hood, Lee

AU - Iyengar, Ravi

AU - Jackson, Vicky

AU - Kallioniemi, Ollie

AU - Klingmüller, Ursula

AU - Kolar, Patrik

AU - Kolch, Walter

AU - Kyriakopoulou, Christina

AU - Laplace, Frank

AU - Lehrach, Hans

AU - Marcus, Frederick

AU - Matrisian, Lynn

AU - Nolan, Garry

AU - Pelkmans, Lucas

AU - Potti, Anil

AU - Sander, Chris

AU - Seljak, Marija

AU - Singer, Dinah

AU - Sorger, Peter

AU - Stunnenberg, Hendrik

AU - Superti-Furga, Giulio

AU - Uhlen, Mathias

AU - Vidal, Marc

AU - Weinstein, John

AU - Wigle, Dennis A

AU - Williams, Michael

AU - Wolkenhauer, Olaf

AU - Zhivotovsky, Boris

AU - Zinovyev, Andrei

AU - Zupan, Blaž

PY - 2009/2

Y1 - 2009/2

N2 - The main conclusion is that systems biology approaches can indeed advance cancer research, having already proved successful in a very wide variety of cancer-related areas, and are likely to prove superior to many current research strategies. Major points include:•Systems biology and computational approaches can make important contributions to research and development in key clinical aspects of cancer and of cancer treatment, and should be developed for understanding and application to diagnosis, biomarkers, cancer progression, drug development and treatment strategies.•Development of new measurement technologies is central to successful systems approaches, and should be strongly encouraged. The systems view of disease combined with these new technologies and novel computational tools will over the next 5-20 years lead to medicine that is predictive, personalized, preventive and participatory (P4 medicine).•Major initiatives are in progress to gather extremely wide ranges of data for both somatic and germ-line genetic variations, as well as gene, transcript, protein and metabolite expression profiles that are cancer-relevant. Electronic databases and repositories play a central role to store and analyze these data. These resources need to be developed and sustained.•Understanding cellular pathways is crucial in cancer research, and these pathways need to be considered in the context of the progression of cancer at various stages. At all stages of cancer progression, major areas require modelling via systems and developmental biology methods including immune system reactions, angiogenesis and tumour progression.•A number of mathematical models of an analytical or computational nature have been developed that can give detailed insights into the dynamics of cancer-relevant systems. These models should be further integrated across multiple levels of biological organization in conjunction with analysis of laboratory and clinical data.•Biomarkers represent major tools in determining the presence of cancer, its progression and the responses to treatments. There is a need for sets of high-quality annotated clinical samples, enabling comparisons across different diseases and the quantitative simulation of major pathways leading to biomarker development and analysis of drug effects.•Education is recognized as a key component in the success of any systems biology programme, especially for applications to cancer research. It is recognized that a balance needs to be found between the need to be interdisciplinary and the necessity of having extensive specialist knowledge in particular areas.•A proposal from this workshop is to explore one or more types of cancer over the full scale of their progression, for example glioblastoma or colon cancer. Such an exemplar project would require all the experimental and computational tools available for the generation and analysis of quantitative data over the entire hierarchy of biological information. These tools and approaches could be mobilized to understand, detect and treat cancerous processes and establish methods applicable across a wide range of cancers.

AB - The main conclusion is that systems biology approaches can indeed advance cancer research, having already proved successful in a very wide variety of cancer-related areas, and are likely to prove superior to many current research strategies. Major points include:•Systems biology and computational approaches can make important contributions to research and development in key clinical aspects of cancer and of cancer treatment, and should be developed for understanding and application to diagnosis, biomarkers, cancer progression, drug development and treatment strategies.•Development of new measurement technologies is central to successful systems approaches, and should be strongly encouraged. The systems view of disease combined with these new technologies and novel computational tools will over the next 5-20 years lead to medicine that is predictive, personalized, preventive and participatory (P4 medicine).•Major initiatives are in progress to gather extremely wide ranges of data for both somatic and germ-line genetic variations, as well as gene, transcript, protein and metabolite expression profiles that are cancer-relevant. Electronic databases and repositories play a central role to store and analyze these data. These resources need to be developed and sustained.•Understanding cellular pathways is crucial in cancer research, and these pathways need to be considered in the context of the progression of cancer at various stages. At all stages of cancer progression, major areas require modelling via systems and developmental biology methods including immune system reactions, angiogenesis and tumour progression.•A number of mathematical models of an analytical or computational nature have been developed that can give detailed insights into the dynamics of cancer-relevant systems. These models should be further integrated across multiple levels of biological organization in conjunction with analysis of laboratory and clinical data.•Biomarkers represent major tools in determining the presence of cancer, its progression and the responses to treatments. There is a need for sets of high-quality annotated clinical samples, enabling comparisons across different diseases and the quantitative simulation of major pathways leading to biomarker development and analysis of drug effects.•Education is recognized as a key component in the success of any systems biology programme, especially for applications to cancer research. It is recognized that a balance needs to be found between the need to be interdisciplinary and the necessity of having extensive specialist knowledge in particular areas.•A proposal from this workshop is to explore one or more types of cancer over the full scale of their progression, for example glioblastoma or colon cancer. Such an exemplar project would require all the experimental and computational tools available for the generation and analysis of quantitative data over the entire hierarchy of biological information. These tools and approaches could be mobilized to understand, detect and treat cancerous processes and establish methods applicable across a wide range of cancers.

KW - Cancer

KW - EU-USA workshop

KW - Systems biology

UR - http://www.scopus.com/inward/record.url?scp=59149098946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149098946&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2008.11.003

DO - 10.1016/j.molonc.2008.11.003

M3 - Article

C2 - 19383362

AN - SCOPUS:59149098946

VL - 3

SP - 9

EP - 17

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 1

ER -